Paramita Ghosh

image of Paramita Ghosh



Urology - Medicine
Biochemistry and Molecular Medicine

Offices and Labs

Rm 1132, Oak Park Research Building, 2700 Stockton Blvd, Sacramento, CA 95817
+1 916 734 7805
Bldg 700, Rm 5A026, VA Northern California, Mather, CA
+1 916 843 9336
+1 916 275 3246

Profile Introduction

Paramita Ghosh studies the signal transduction pathways involved in the development and progression of prostate cancer. Advanced prostate cancer is treated by hormonal manipulation using various drugs that affect a steroid nuclear receptor called the androgen receptor. However, patients on this treatment eventually become resistant to this treatment. The overall goal of Dr. Ghosh's lab is to find ways by which resistance to the androgen receptor inhibitors can be overcome. Based on work done in her lab, a clinical trial was recently completed by UC Davis oncologists that demonstrated how a combination of two FDA approved drugs can be used to overcome resistance to each of these drugs. Her lab uses a number of biochemical and molecular biological techniques to achieve these goals. Dr. Ghosh currently has three graduate students and will welcome volunteer undergraduate students who will be working on these projects.


1994 PhD Chemistry Rensselaer Polytechnic Institute
1988 MS Physics Jadavpur University, Calcutta, INDIA
1986 BS Physics Jadavpur University, Calcutta, INDIA

Research Contribution

Dr. Ghosh’s chief topic of research over the last six years has been the elucidation of signal transduction pathways leading to the development of androgen-independent prostate cancer. Her current research is based on the initial observation that in poorly differentiated prostate cancers, Akt, a downstream target of the phosphatidylinositol 3-kinase (PI3K) pathway, is highly phosphorylated. Based on these observations, she has investigated, over the last few years, the role of Akt in the progression of prostate cancer to an androgen-independent state. Currently, she is engaged in studying signal transduction pathways both upstream and downstream of Akt. Upstream of Akt, she is studying the effect of receptor tyrosine kinases and their effects on both the PI3K and the MAPK cell signaling pathways, while downstream of Akt, she is studying the cross-talk with the androgen receptor pathway, and the effects of aging on the development of prostate cancer. At present, her targets of investigation include the erbB family of receptor tyrosine kinases, the andogen receptor, the cytoskeletal scaffolding molecule Filamin A which is known to be an androgen receptor coregulator and components of the signal transduction pathways downstream of Ras (including the mitogen activated protein kinases) and the mammalian target of rapamycin (mTOR), including p70 S6 kinase, 4E-BP1 and e1F-4G.

Research Interests

Signal Transduction Pathways in Prostate Cancer

The pathways we study include the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, the Ras/Raf/MEK/MAPK pathway and other signaling pathways both upstream and downstream of these. This includes the mammalian target of rapamycin (mTOR) pathway, and signaling by the epidermal growth factor receptor (EGFR), related receptor tyrosine kinases ErbB2 and ErbB3.


2000 WICR Young Investigator Scholar Award. American Association for Cancer Research
1997-1999 NIH Postdoctoral Training Award. Department of Pathology, University of Texas Health Science Center at San Antonio, TX.
1989-1994 Tuition Scholarship and Graduate Assistantship. Rensselaer Polytechnic Institute, Troy, NY
1989 Gold Medal for Excellence, Master of Science. Department of Physics, Jadavpur University, Calcutta 700032, India
1989 S.N. Bose Medal for best academic achievement. Department of Physics, Jadavpur University, Calcutta 700032, India.
1983-1989 National Science Scholarship. University Grants Commission, Government of India
2006 UC Davis Academic Federation Travel Award
2006 Best Poster Award. International Symposium on Hormonal Carcinogenesis, Montpellier, France
2010 Travel Award, 6th International Symposium on Hormonal Oncogenesis, Tokyo, Japan.
2007 California Coalition to Cure Prostate Cancer Award, ($26,000) Prostate Cancer Foundation, Santa Monica, CA
2013 Scientist Selected to Join Global Task Force focused on Cancer Causing Potential of Chemicals (Getting to know Cancer)
2016 “Exceptional Women in Endocrine Cancer” profile, Endocrine Related Cancers, 2016.

Department and Center Affiliations

Department of Urology, School of Medicine
UC Davis Cancer Center
Department of Biochemistry and Molecular Medicine


American Association for Cancer Research
Society of Basic Urological Research
American Association for the Advancement of Science
American Society for Cell Biology

CBS Grad Group Affiliations

Biochemistry, Molecular, Cellular and Developmental Biology
Integrated Genetics and Genomics

Specialties / Focus

Biochemistry, Molecular, Cellular and Developmental Biology
  • Cancer Biology
  • Cell Division and the Cytoskeleton
  • Signal Transduction
Integrated Genetics and Genomics
  • Integrated Genetics and Genomics

Graduate Groups not Housed in CBS

Comparative Pathology
Pharmacology and Toxicology (PTX)


Postdoctoral Fellows website
  • Salma Siddiqui
Graduate Students
  • Maitreyee Jathal (PhD student)
  • Zsofia Kiss (PhD Student)
  • Leandro D'Abronzo (PhD student);
Research Associate
  • Thomas Steele
  • Mike Crapuchettes
Undergraduate Volunteers
  • Jonathan Phillips

Teaching Interests

Cell and Molecular Biology Biochemistry


PMI 298 Foundations in Research (Fall)
BCB 298 Signal Transduction Pathways (Spring)
BCM 410A Molecular and Cell Biology (Fall)


6/18/2017 10:20:24 PM
  • Shih TC, Liu R, Fung G, Bhardwaj G, Ghosh PM, Lam KS. (2017) A Novel Galectin-1 Inhibitor Discovered through One-Bead Two-Compound Library Potentiates the Antitumor Effects of Paclitaxel in vivo. Molecular cancer therapeutics .
  • Kiss Z, Ghosh PM. Circadian rhythmicity and the influence of 'clock' genes on prostate cancer.Endocr Relat Cancer. 2016 Sep 22. pii: ERC-16-0366. [Epub ahead of print].

  • Ghosh PM. From physics to cancer biology and everywhere in between. Endocr Relat Cancer. 2016 Sep 7. pii: ERC-16-0382. [Epub ahead of print]

  • Vinall, R.L., Tepper, C.G., Ripoll, A.Z., Gandour- Edwards, R.F., Durbin-Johnson, B.P., Yap, S.A., Ghosh, P.M. and deVere White, R.W. Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy. Genes & Cancer, Vol. 7 (3-4): 86-97, March 2016.

  • Lombard, A. P., Mooso, B. A., Libertini, S. J., Lim, R. M., Nakagawa, R., Vidallo, K., Costanzo, N., Ghosh, P. M., Mudryj, M. miR-148a Dependent Apoptosis of Bladder Cancer Cells is Mediated in Part by the Epigenetic Modifier DNMT1. Molecular Carcinogenesis, 2016 May;55(5):757-67. (PMID: 25865490)

  • Chow, H., Ghosh, PM, deVere White, RW, Evans, CP, Dall’Era, MA, Yap, SA, Li, Y, Beckett, LA, Lara, PN, Pan, CX. A Phase II clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 Jun 15;122(12):1897-904. PMID: 27019001.

  • D'Abronzo LS, Ghosh PM. Medical Treatment of Urological Malignancies. Stief CG, Fizazi K, Evans CP, editors. Lisbon: International Consultation on Medical Treatment of Urological Malignancies; 2015. Chapter Section X, The Akt/PI3K/PTEN pathway as a driver and therapeutic target in castration-resistant prostate cancer; p.325-336.

  • Pan, C.-x., Zhang, H., Tepper, C. G., Lin, T.-y., Davis, R. R., Keck, J., Ghosh, P. M., Gill, P., Airhart, S., Bult, C., Gandara, D. R., Liu, E., de Vere White, R. W. Development and characterization of bladder cancer patient-derived xenografts for molecularly guided targeted therapy. PLOS ONE. 2015 Aug 13;10(8):e0134346. PMID: 26270481

  • Narayanan, K.N., Ali, M., Barclay, B., Cheng, Q.S., D'Abronzo, L.S., Dornetshuber-Fleiss, R., Ghosh, P.M., et al, Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death. Carcinogenesis, 2015. ** Jun;36 Suppl 1:S89-S110**. PMID: 26106145

  • Goodson, W.H. III, Lowe, L., ….., Ghosh, P.M., et al. Assessing the Carcinogenic Potential of Low Dose Exposures to Chemical Mixtures in the Environment: The Challenge Ahead. Carcinogenesis, 2015. ** Jun;36 Suppl 1:S254-96**. PMID: 26106142

  • Savoy, R.M., Chen, L., Siddiqui, S., Melgoza, F.U., Durbin-Johnson, B., Drake, C., Jathal, M.K., Bose, S., Steele, T.M., Mooso, B.A., D’Abronzo, L.S., Fry, W.H., Carraway, K.L. III, Mudryj, M. and Ghosh, P.M. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear Filamin A in prostate cancer. Endocrine-related Cancer, 2015. Jun; 22(3):369-86 (PMID: 25759396).

  • Mooso, B.A., Vinall, R.L., Mudryj, M., Yap, S.A., deVere White, R.W., Ghosh, P.M. The Role of EGFR Family Inhibitors in Muscle-Invasive Bladder Cancer. Journal of Urology. 2015. Jan;193(1):19-29.

  • Ghosh P, Qiu Y, Wang LY and Kung HJ: Tyrosine kinome profiling: Oncogenic mutations and therapeutic targeting in cancer, Molecular Oncology – Causes of Cancer ad Targets for Treatment. Eds. Gelmann, E.P., Sawyers, C.L. and Rauscher, F.J. Cambridge University Press. pages 58-75. Feb 2014.

  • Ghosh PM and A.C. Gao. Zoledronic acid at the time of castration prevented castration-induced bone metastasis in mice. Endocrine related Cancers. 2014. Oct;21(5):C11-4

  • Ghosh PM. Editorial Comments on “The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer?”. J. Urology. 2013 Nov;190(5):1697

  • Savoy RM, Ghosh PM. The changing roles of steroid nuclear receptors with prostate cancer progression. Endocr Relat Cancer. 2013 Jul 4;20(4):C9-11.

  • Savoy RM, Ghosh PM. Linking inflammation and neuroendocrine differentiation: the role of macrophage migration inhibitory factor-mediated signaling in prostate cancer. Endocr Relat Cancer. 2013 May 21;20(3):C1-4.

  • Savoy RM, Ghosh PM. The dual role of filamin A in cancer: can't live with (too much of) it, can't live without it. Endocr Relat Cancer. 2013 Nov 4;20(6):R341-56.

  • Mooso BA, Vinall RL, Tepper CG, Savoy RM, Cheung JP, Singh S, Siddiqui S, Wang Y, Bedolla RG, Martinez A, Mudryj M, Kung HJ, Devere White RW, Ghosh PM. Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. Endocr Relat Cancer. 2012 Nov 9;19(6):759-77.

  • Ghosh, P.M.,  Shu, Z.J., Zhu, B., Lu, Z., Ikeno, Y., Barnes, J.L., Yeh, C.K., Zhang, B.K., Katz, M.S. and Kamat, A. β-Adrenergic Receptor Signaling Increases Lipid Accumulation In Liver During Aging. Journal of Endocrinology 2012 Jun;213(3):251-61.

  • Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L, Vinall RL, deVere White RW, Ghosh PM. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res. 2011 Oct 1; 17 (19):6218-28.
  • Vinall RL, Mahaffey CM, Davis RR, Luo Z, Gandour-Edwards R, Ghosh PM, Tepper CG, de Vere White RW. Dual blockade of PKA and NF-B inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. Horm Cancer. 2011 Aug; 2 (4):224-38. PubMed PMID: 21789713.
  • Jathal MK, Chen L, Mudryj M, Ghosh PM. Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block. Immunol Endocr Metab Agents Med Chem. 2011 Jun; 11 (2):131-149. PubMed PMID: 21603064
  • Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: role of cholesterol inhibition vs prevention of small GTP-binding proteins. Am J Cancer Res. 2011; 1 (4):542-61. PubMed PMID: 21984972.
  • Ghosh PM. What controls PTEN and what it controls (in prostate cancer). Asian J Androl. 2011 Sep 26; 14(1): 130-131. PubMed PMID: 21946231.

  • Chen H, Libertini SJ, Wang Y, Kung HJ, Ghosh P, Mudryj M. ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. J Biol Chem. Jan 22;285(4):2368-74. 2010
  • Chen, L, Lu, X.-H., Shi, X.-B., R., deVere White, RW, Carraway, K.L. III and Ghosh, PM. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate–resistant prostate cancer cells. Cancer Research. 70(14):5994-6003, 2010.
  • Mooso, B., Madhav, A. Johnson, S.D., Roy, M., Moore, M.E., Moy, C., Loredo, Mehta, R.G., Vaughan, A.T.M. and Ghosh, P.M. Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 – a calcitriol analog. Genes and Cancer, 2010. Nov 16;1(9):927-940.
  • Chen, H., Libertini, S.J., George, M., Dandekar, S., Tepper, C.G., Al-Bataina, B., Kung, H.-J., Ghosh, P.M., Mudryj, M. Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocrine-related cancers. 2010. Oct 5;17(4):857-73.
  • Khan, IH, Zhao, J, Ghosh, PM, Ziman, M, Sweeney, C, Kung, HJ and Luciw, PA. Activation and Dimerization of Receptor Tyrosine Kinases (ErbB Family) in Breast Cancer Cells Analyzed by Multiplex Microbead Suspension Array. ASSAY and Drug Development Technologies. Feb;8(1):27-36. 2010
  • Ghosh P, Qiu Y, Wang LY and Kung HJ: Tyrosine kinome profiling: Oncogenic mutations and therapeutic targeting in cancer, Molecular Oncology – Causes of Cancer ad Targets for Treatment. Eds. Gelmann, E.P., Sawyers, C.L. and Rauscher, F.J. Cambridge University. 58-75. 2014

  • Bedolla, RG, Asuncion, A, Chamie, K, Siddiqui, S, Troyer, DA, Mehra, R, Siddiqui, J, Chinnaiyan, AM, deVereWhite, RW, and Ghosh, PM. Nuclear vs Cytoplasmic localization of Filamin A in Prostate Cancer: Immunohistochemical Correlation with Metastases. Clinical Cancer Research, 15(3): 788-796. 2009.
  • Chamie, K, Ghosh, PM, Koppie, TM, Romero, V, Troppmann, C,and deVere White, RW. The effect of sirolimus on PSA kinetics in male renal transplant recipients without prostate cancer. American Journal of Transplantation, 8(12): 2668-2673. 2008.
  • Wang, Y, Mikhailova, M, deVere White, RW, and Ghosh, PM. Regulation of androgen receptor transcriptional activity by rapamycin. Oncogene, 27(56): 7106-7117. 2008
  • Kamat, A., Ghosh, PM, Glover, RL, Zhu, B, Yeh, CK, Choudhury, GG and Katz, MS. Reduced Expression of Epidermal Growth Factor Receptors in. Journal of Gerontology, 63(7): 683-692. 2008
  • Mikhailova, M., Wang, Y., Bedolla, R.G., Lu, X.H., Kreisberg, J.I. and Ghosh, P.M.: AKT Regulates Androgen Receptor-dependent Growth and PSA Expression in Prostate Cancer, Adv Exp Med Biol., Vol. 617, pp. 397-405. 2008.
  • Wang, Y., Kreisberg, J.I. and Ghosh, P.M. Cross-talk between the Androgen Receptor and the Phosphatidylinositol 3-kinase/Akt pathway in Androgen-Independent Prostate Cancer. Current Cancer Drug Targets. 7: 591-604. 2007
  • Shi, X.-B., Xue, L. Tepper, C.G., Gandour-Edwards, R., Ghosh, P., Kung, H.J. and deVere White, R.W. . The oncogenic potential of a prostate cancer-derived androgen receptor mutant. The Prostate, 67(6): 591-602. 2007.
  • Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA, Ghosh PM. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin. Cancer Res., 13(13): 3860-3867. 2007
  • Wang, Y., Kreisberg, J.I., Bedolla, R., Mikhailova, M., deVere White, R.W. and Ghosh, P.M. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells. Oncogene. 2007.
  • Mikhailova M, Wang Y, Bedolla RG, Lu XH, Kreisberg JI and Ghosh PM: AKT Regulates Androgen Receptor-dependent Growth and PSA Expression in Prostate Cancer, Adv Exp Med Biol, Vol. 617, pp. 397-405. 2007.

  • Vinall, R.L., Hwa, K., Ghosh, P., Pan, C-X., Lara, P.N. Jr. and deVere White, R.W. Combination Treatment Of Prostate Cancer Cell Lines With Bioactive Soy Isoflavones (GCP) And Perifosine Causes Increased Growth Arrest And/Or Apoptosis. Clinical Cancer Research. 13: 6204-6216. 2007.
  • Wang, Y., Kreisberg, J.I. and Ghosh, P.M. Cross-talk between the Androgen Receptor and the Phosphatidylinositol 3-kinase/Akt pathway in Androgen-Independent Prostate Cancer. Current Cancer Drug Targets. 7: 591-604. 2007
  • Vinall, R.L., Hwa, K., Ghosh, P., Pan, C-X., Lara, P.N. Jr. and deVere White, R.W. Combination Treatment Of Prostate Cancer Cell Lines With Bioactive Soy Isoflavones (GCP) And Perifosine Causes Increased Growth Arrest And/Or Apoptosis. Clinical Cancer Res., 13: 6204-6216, 2007
  • Ghosh, P.M., Malik, S.N., Prihoda, T.J., Bedolla, R.G., Wang, Y., Troyer, D.A. and Kreisberg, J.I. Akt mediates proliferation via both androgen-dependent and independent pathways in prostate cancer. Endocr Relat Cancer. Mar;12(1):119 34. 2005
  • Yeh, C. K.**, Ghosh, P.M.**, Liu, Q., Zhang, B. X., and Katz, M.S. Activation of Mitogen-activated Protein Kinase Mediates Isoproterenol-induced Salivary Cell Growth. Am J Physiol Cell Physiol. 288(6):C1357-C1366. 2005
  • Ghosh, P.M., Bedolla, R., Thomas, C.A. and Kreisberg, JI. Role of Protein kinase C in Arginine Vasopressin-stimulated mesangial cell proliferation. J. Cell. Biochem., 2004; 91(6):1109-29.
  • Kreisberg, J.I., Malik, S.N., Prihoda, T.J., Bedolla, R.G., Troyer, D.A. Kreisberg, S. and Ghosh, P.M. Expression of phospho-AKT (Ser 473) is an excellent predictor of Poor Clinical Outcome in Prostate Cancer. Cancer Res. Aug 1;64(15):5232-6. 2004
  • Ghosh, P.M., Malik, S. N., Bedolla, R. and Kreisberg, J.I. Akt in Prostate Cancer: Possible Role in Androgen-Independence. Current Drug Metabolism, 4(6):487-496. 2003
  • Ghosh PM, Bedolla R, Mikhailova M, and Kreisberg JI. RhoA-Dependent Murine Prostate Cancer Cell Proliferation and Apoptosis: Role of PKCzeta. Cancer Res. 62(9):2630-6. 2002
  • Malik, S.N., Brattain, M.G., Ghosh, P.M., Troyer, D.A., Prihoda, T., Bedolla, R. and Kreisberg, J.I. Immunohistochemical Demonstration of phospho-Akt in High Gleason Grade Prostate Cancer. Clinical Cancer Res. 8(4):1168-71. 2002
  • Sawhney RS, Guo-Hao K, Humphrey LE, Ghosh P, Kreisberg JI, Brattain MG: Differences in sensitivity of biological functions mediated by epidermal growth factor receptor activation with respect to endogenous and exogenous ligands. J Biol Chem 277: 75-86. 2002
  • Ghosh, P.M., Mikhailova, M., Bedolla, R. and Kreisberg, J.I. Arginine Vasopressin Stimulates Mesangial Cell Proliferation by Activating the Epidermal Growth Factor Receptor. Am. J. Physiol- Renal Physiology. 280(6):F972-979. 2001
  • Ghosh-Choudhury, N., Ghosh-Choudhury, G., Celeste, A., Ghosh, P.M., Moyer, M.L., Abboud, S.L., and Kreisberg, J.I. Bone Morphogenic Protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol treated MCF- human breast cancer cells. Biochim. Biophys. Acta 1497:186-196. 2000
  • Ghosh, P.M., M. Moyer and J.I. Kreisberg. Effect of cyclin E overexpression on lovastatin-induced G1 arrest and RhoA inactivation in NIH3T3 cells. J. Cell. Biochem. 74: 532  543. 1999
  • Ghosh, P.M., G.E. Mott, M.L. Stapleton, N. Ghosh-Choudhury and J.I. Kreisberg. Role of RhoA and actin stress fiber formation in the proliferation of a mouse prostate cancer cell line. Oncogene. 18: 4120-4130. 1999
  • Ghosh, P., G.E. Mott, N. Ghosh-Choudhury, R.A. Radnik, M.L. Stapleton, J.J. Ghidoni and J.I. Kreisberg. Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells. Biochim. Biophys. Acta. 1359: 13-24. 1997
  • Klebe, R.J., A. Grant, G. Grant and P. Ghosh. 1995. Cyclic-AMP deficient MDCK cells from tubules. J. Cell Biochem. 59:453-462. 1995
  • Klebe, R.J., C.A. Thomas, G.M. Grant, A. Grant and P. Ghosh. Cytoscription: Computer-controlled micropositioning of cell adhesion proteins. J. Tissue Culture Methods. 16:189-192. 1994
  • Ghosh, P.M., C.R. Keese and I. Giaever. Morphological response of mammalian cells to pulsed AC fields. Bioelectrochem. Bioenerg. 33:121-133. 1994
  • Ghosh, P.M., C.R. Keese and I. Giaever. Monitoring Electropermeabilization in the Plasma Membrane of Adherent Mammalian Cells. Biophys. J. 64: 1602-1609. 1993
  • Mitra, P., C.R. Keese and I. Giaever. Electrical Measurements can be used to Monitor the Attachment and Spreading of Cells in Tissue Culture. Biotechniques. 11: 504-510. 1991